100481-09-2

Basic information

• Product Name: 2-Thiazolesulfonyl chloride
• Synonyms: 2-THIAZOLESULFONYL CHLORIDE;2-Thiazolesulfonylchloride(9CI);Thiazolesulfonyl chloride;thiazole-2-sulfonyl chloride;1,3-thiazole-2-sulfonyl chloride
• CAS NO: 100481-09-2
• Molecular Formula: C₃H₂ClNO₂S₂
• Molecular Weight: 183.64
• Product Categories: SULFONYLHALIDE;Thiazoles;Heterocycles;Sulfur & Selenium Compounds
• Mol File: 100481-09-2.mol

Chemical Properties

• Boiling Point: 328.523 °C at 760 mmHg
• Flash Point: 152.486 °C
• Appearance: Yellow oil
• Density: 1.688 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.583
• Storage Temp.: -86?C Freezer, Under Inert Atmosphere
• Solubility: Chloroform (Slightly), Ethyl Acetate (Slightly)
• PKA: -3.33±0.10(Predicted)
• CAS DataBase Reference: 2-Thiazolesulfonyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Thiazolesulfonyl chloride(100481-09-2)
• EPA Substance Registry System: 2-Thiazolesulfonyl chloride(100481-09-2)

Safety Data

• Hazardous Substances Data: 100481-09-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Thiazolesulfonyl chloride is used as a synthetic intermediate for the preparation of substituted thiazolesulfonamides. These compounds have potential applications as antiglaucoma agents, which are crucial in the treatment of glaucoma, a group of eye conditions that can lead to vision loss.

InChI:InChI=1/C3H2ClNO2S2/c4-9(6,7)3-5-1-2-8-3/h1-2H

Upstream product

• 3034-53-5 2-bromo-1,3-thiazole 
• 5685-05-2 2-mercaptothiazole 
• 288-47-1 1,3-thiazole 
• 109-72-8 n-butyllithium 

Downstream Products

• 909896-97-5 methyl 4-{[2-[(1,3-thiazol-2-ylsulfonyl)amino]-5-(trifluoromethyl)phenoxy]methyl}benzoate 
• 916913-90-1 methyl 4-({4,5-dimethyl-2-[(1,3-thiazol-2-ylsulfonyl)amino]phenoxy}methyl)benzoate 
• 916913-92-3 methyl 4-({4,5-dimethyl-2-[(1,3-thiazol-2-ylsulfonyl)amino]phenoxy}methyl)-3-methylbenzoate 
• 916913-91-2 methyl 4-[({6-[(1,3-thiazol-2-ylsulfonyl)amino]-2,3-dihydro-1H-inden-5-yl}oxy)methyl]benzoate 
• 916913-93-4 methyl 3-methyl-4-[({6-[(1,3-thiazol-2-ylsulfonyl)amino]-2,3-dihydro-1H-inden-5-yl}oxy)methyl]benzoate 
• 1257229-78-9 (2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methyl-1-(1,3-thiazol-2-ylsulfonyl)piperazine 
• 1313217-19-4 tert-butyl [tert-butoxycarbonyl(6-{[4-(1,1-dimethylpentyl)benzyl](thiazol-2-ylsulfonyl)aminomethyl}pyridin-2-yl)amino]acetate 
• 1388234-62-5 2-(4-(4-((1,3-thiazol-2-yl)sulfonyl)-2-(1-propyn-1-yl)-1-piperazinyl)phenyl)-1,1,1,3,3,3-hexafluoro-2-propanol 

Relevant articles and documents

Design and in vitro activities of N -alkyl- N -[(8- R -2,2-dimethyl-2 H -chromen-6-yl)methyl]heteroarylsulfonamides, novel, small-molecule hypoxia inducible factor-1 pathway inhibitors and anticancer agents

The hypoxia inducible factor (HIF) pathway is an attractive target for cancer, as it controls tumor adaptation to growth under hypoxia and mediates chemotherapy and radiation resistance. We previously discovered 3,4-dimethoxy-N-[(2,2-dimethyl-2H-chromen-6-yl)methyl]-N- phenylbenzenesulfonamide as a novel, small-molecule HIF-1 pathway inhibitor in a high-throughput cell-based assay, but its in vivo delivery is hampered by poor aqueous solubility (0.009 μM in water; log P7.4 = 3.7). Here we describe the synthesis of 12 N-alkyl-N-[(8-R-2,2-dimethyl-2H-chromen-6-yl) methyl]heteroarylsulfonamides, which were designed to possess optimal lipophilicities and aqueous solubilities by in silico calculations. Experimental log P7.4 values of 8 of the 12 new analogs ranged from 1.2-3.1. Aqueous solubilities of three analogs were measured, among which the most soluble N-[(8-methoxy-2,2-dimethyl-2H-chromen-6-yl)methyl]-N-(propan-2-yl) pyridine-2-sulfonamide had an aqueous solubility of 80 μM, e.g., a solubility improvement of ～9000-fold. The pharmacological optimization had limited impact on drug efficacy as the compounds retained IC50 values at or below 5 μM in our HIF-dependent reporter assay.

Synthesis of the Privileged 8-Arylmenthol Class by Radical Arylation of Isopulegol

Hydrogen atom transfer (HAT) circumvents a disfavored Friedel-Crafts reaction in the derivatization of the inexpensive monoterpene isopulegol. A variety of readily prepared aryl and heteroaryl sulfonates undergo a formal hydroarylation to form 8-arylmenthols, privileged scaffolds for asymmetric synthesis, as typified by 8-phenylmenthol. High stereoselectivity is observed in related systems. This use of HAT significantly extends the chiral pool from the inexpensive monoterpene isopulegol.

PLATELET ADP RECEPTOR INHIBITORS

no abstract published

HETEROCYCLIC AMIDE DERIVATIVE AND MEDICINE CONTAINING SAME

Compound represented by formula (I): wherein each symbol is as defined herein, exhibit TRPA1 antagonist activity, and are useful for the prophylaxis or treatment of diseases involving TRPA1 antagonist and TRPA1.

11-BETA HSD1 1NHIBITORS

This invention features a chemical entity E, which is a compound of Formula I, or a salt (e.g., a pharmaceutically acceptable salt), or an N-oxide thereof (e.g., a compound of Formula I, or a pharmaceutically acceptable salt thereof). Formula I is provided below: formula (I) R1, R2, R3, R4, R5, R6, R7, R8, R9, and A can be as defined anywhere herein

Discovery of heteroaryl sulfonamides as new EP1 receptor selective antagonists

4-({2-[Isobutyl(phenylsulfonyl)amino]-5-(trifluoromethyl)phenoxy}methyl)benzoic acid (1) is a functional PGE2 antagonist selective for EP1 receptor subtype. Analogs of 1, in which the phenyl-sulfonyl moiety has been replaced with more hydrophil

Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin

Biphenylsulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, bicyclic or tricyclic carbon or heterocyclic ring biphenylsulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.

N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin

Thienyl-, furyl- and pyrrolyl-sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.

THIENYL-, FURYL- AND PYRROLYL SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN

Thienyl-, furyl-and pyrrolyl-sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl) furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.